• BioTime Inc., of Alameda, Calif., created subsidiary BioTime Acquisition Corp. (BAC), for an agreement with Geron Corp., of Menlo Park, Calif., to acquire Geron's human embryonic stem cell (hESC) program, including its Phase I hESC-derived oligodendrocytes for acute spinal cord injury and its autologous cellular immunotherapy program.